Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition.

Maryam Hosseini, Kaveh Baghaei, Davar Amani, Masoumeh Ebtekar
{"title":"Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition.","authors":"Maryam Hosseini,&nbsp;Kaveh Baghaei,&nbsp;Davar Amani,&nbsp;Masoumeh Ebtekar","doi":"10.1007/s40199-021-00400-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>MicroRNA (miR)-34a, as a master tumor suppressor in colorectal cancer (CRC), could regulate multiple genes participating in tumor proliferation, invasion, immune evasion, and inflammation-induced progression. Exosomes, as novel nano-carriers, were found to be capable of shuttling crucial mediators to various cells. Since the conventional CRC therapeutics currently are a matter of debate, implication of microRNAs in malignancy remedies have been addressed illustrating promising outlooks.</p><p><strong>Objectives: </strong>In this study, we aimed to investigate the delivery of miR-34a to CRC cell line CT-26 by encapsulating into tumor-derived exosomes (TEXs), in order to evaluate the anti-proliferative and progressive effects of the novel nano-carrier complex under in vitro condition.</p><p><strong>Methods: </strong>Exosomes were purified from the starved CT-26 cells and then enriched by miR-34a using the calcium chloride (Cacl<sub>2</sub>) modified solution. Following the detection of miR-34a expression in the enriched TEXs, the viability of CT-26 cells treated by multiplicity concentrations of either TEXs or TEX-miR-34a was examined. Moreover, the apoptosis rate of the cells was evaluated, and the migration of CT-26 cells subjected to both TEX-miR-34a and TEX was also measured. Thereafter, the expressions of miR-34a target genes, as IL-6R, STAT3, PD-L1, and VEGF-A, which play roles in tumor progression, were determined in the treated CT-26 cells.</p><p><strong>Results: </strong>The viability of CT-26 cells was harnessed following the treatment with TEX-miR-34a and the apoptosis levels of the cells were also observed to be enhanced dose-dependently. TEX-miR-34a was able to diminish the migration rate of the TEX-miR-34a treated cells and the expressions of IL-6R, STAT3, PD-L1, and VEGF-A were significantly restricted. Moreover, TEXs alone increased the apoptosis rate of tumor cells and repressed the proliferation and migration of these cells which were boosted by enrichment of TEXs with miR-34a.</p><p><strong>Conclusion: </strong>Exosomes isolated from the starved CT-26 cells were found to have a potential to deliver miR-34a into tumor cells properly with high functionality maintenance for miR-34a in case of regulating genes related to tumor progression and TEXs which showed no positive effect favoring cancer cells, presumably act as a favorable adjuvant in the CRC therapy.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 2","pages":"267-278"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-021-00400-0","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40199-021-00400-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Background: MicroRNA (miR)-34a, as a master tumor suppressor in colorectal cancer (CRC), could regulate multiple genes participating in tumor proliferation, invasion, immune evasion, and inflammation-induced progression. Exosomes, as novel nano-carriers, were found to be capable of shuttling crucial mediators to various cells. Since the conventional CRC therapeutics currently are a matter of debate, implication of microRNAs in malignancy remedies have been addressed illustrating promising outlooks.

Objectives: In this study, we aimed to investigate the delivery of miR-34a to CRC cell line CT-26 by encapsulating into tumor-derived exosomes (TEXs), in order to evaluate the anti-proliferative and progressive effects of the novel nano-carrier complex under in vitro condition.

Methods: Exosomes were purified from the starved CT-26 cells and then enriched by miR-34a using the calcium chloride (Cacl2) modified solution. Following the detection of miR-34a expression in the enriched TEXs, the viability of CT-26 cells treated by multiplicity concentrations of either TEXs or TEX-miR-34a was examined. Moreover, the apoptosis rate of the cells was evaluated, and the migration of CT-26 cells subjected to both TEX-miR-34a and TEX was also measured. Thereafter, the expressions of miR-34a target genes, as IL-6R, STAT3, PD-L1, and VEGF-A, which play roles in tumor progression, were determined in the treated CT-26 cells.

Results: The viability of CT-26 cells was harnessed following the treatment with TEX-miR-34a and the apoptosis levels of the cells were also observed to be enhanced dose-dependently. TEX-miR-34a was able to diminish the migration rate of the TEX-miR-34a treated cells and the expressions of IL-6R, STAT3, PD-L1, and VEGF-A were significantly restricted. Moreover, TEXs alone increased the apoptosis rate of tumor cells and repressed the proliferation and migration of these cells which were boosted by enrichment of TEXs with miR-34a.

Conclusion: Exosomes isolated from the starved CT-26 cells were found to have a potential to deliver miR-34a into tumor cells properly with high functionality maintenance for miR-34a in case of regulating genes related to tumor progression and TEXs which showed no positive effect favoring cancer cells, presumably act as a favorable adjuvant in the CRC therapy.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在体外条件下,包封miR-34a的肿瘤源性外泌体促进结直肠癌细胞凋亡,抑制其迁移和肿瘤进展。
背景:MicroRNA (miR)-34a作为结直肠癌(CRC)的主要抑癌因子,可调控参与肿瘤增殖、侵袭、免疫逃避和炎症诱导进展的多个基因。外泌体作为一种新型的纳米载体,能够将关键的介质运送到不同的细胞中。由于传统的结直肠癌治疗方法目前存在争议,microrna在恶性肿瘤治疗中的意义已经得到了解决,并显示出了良好的前景。目的:在本研究中,我们旨在研究miR-34a通过包裹入肿瘤源性外泌体(TEXs)向CRC细胞系CT-26的递送,以评估新型纳米载体复合物在体外条件下的抗增殖和进展作用。方法:从饥饿的CT-26细胞中纯化外泌体,然后用氯化钙(Cacl2)修饰的溶液富集miR-34a。在富集的TEXs中检测miR-34a表达后,检测多重浓度TEXs或TEX-miR-34a处理的CT-26细胞的活力。此外,评估细胞的凋亡率,并测量TEX- mir -34a和TEX作用下CT-26细胞的迁移情况。随后,检测miR-34a靶基因IL-6R、STAT3、PD-L1和VEGF-A在处理后的CT-26细胞中的表达,这些基因在肿瘤进展中起作用。结果:TEX-miR-34a处理后,CT-26细胞的活力得到改善,细胞凋亡水平也呈剂量依赖性增强。TEX-miR-34a能够降低TEX-miR-34a处理细胞的迁移率,IL-6R、STAT3、PD-L1和VEGF-A的表达明显受到限制。此外,单独使用TEXs可提高肿瘤细胞的凋亡率,抑制肿瘤细胞的增殖和迁移,而miR-34a富集TEXs可促进肿瘤细胞的增殖和迁移。结论:从饥饿的CT-26细胞中分离的外泌体被发现有可能将miR-34a适当地递送到肿瘤细胞中,并且在调节肿瘤进展相关基因和TEXs的情况下,miR-34a的功能得到高度维持,而TEXs对癌细胞没有积极作用,可能在CRC治疗中起到有利的辅助作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correction: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies. A rare case of phenobarbital-induced leukocytoclastic vasculitis. Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1